Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 14;15(1):173.
doi: 10.1186/s13014-020-01608-1.

Stereotactic body radiotherapy for localized prostate cancer - 5-year efficacy results

Kristiina Vuolukka  1 , Päivi Auvinen  2   3 , Erno Tiainen  3 , Jan-Erik Palmgren  2 , Janne Heikkilä  2 , Jan Seppälä  2 , Sirpa Aaltomaa  4 , Vesa Kataja  3   5
Affiliations

Stereotactic body radiotherapy for localized prostate cancer - 5-year efficacy results

Kristiina Vuolukka et al. Radiat Oncol. .

Abstract

Background: The use of stereotactic body radiotherapy (SBRT) as the primary treatment modality in clinically localized prostate cancer (PCa) is emerging. The aim of the study was to analyze the long-term results of PCa patients treated with SBRT.

Methods: This non-selected, real-life patient cohort included 213 patients with localized PCa treated with a robotic SBRT device during 2012-2015.

Results: The median follow-up was 64 months (range, 10-85 months), and all risk-groups were represented as 47 (22.1%), 56 (26.3%) and 110 (51.6%) patients were classified into D'Amico risk stratification of low, intermediate and high-risk groups, respectively. Androgen deprivation therapy (ADT) was administered to 64.3% of the patients. At cut-off, the biochemical relapse-free survival (bRFS) was 100, 87.5 and 80.0% for patients at low, intermediate and high-risk (p = 0.004), and 92.5, 84.2 and 66.7% for patients with Gleason score ≤ 6, 7 and ≥ 8, respectively (p = 0.001). The actuarial 5-year overall survival (OS) rates were 97.9, 96.4 and 88.6% in the low, intermediate and high-risk groups, respectively, and at the cut-off, the disease-specific survival (DSS) rate of the whole cohort was high (99.1%), as only two high-risk patients died due to PCa.

Conclusion: Our present results of SBRT delivered with CyberKnife produced excellent long-term bRFS, OS and DSS outcomes among patients with localized PCa. We conclude that SBRT provides an efficient and convenient treatment option for patients with localized PCa, irrespective of the risk-group.

Keywords: Prostate cancer; Radiation therapy; Stereotactic body radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The biochemical relapse-free survival (bRFS) rates at the median follow-up of 64 months according to the risk-group (a) and to the Gleason score (b)
See this image and copyright information in PMC

References

    1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101. doi: 10.1016/s0360-3016(98)00438-6. - DOI - PubMed
    1. Proust-Lima C, Taylor JMG, Sécher S, Sandler H, Kestin L, Pickles T, et al. Confirmation of a low a/b ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys. 2011;79:195–201. doi: 10.1016/j.ijrobp.2009.10.008. - DOI - PMC - PubMed
    1. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: a/b = 1.4 (0.9–2.2) Gy Int J Radiat Oncol Biol Phys. 2012;82:e17–e24. doi: 10.1016/j.ijrobp.2010.10.075. - DOI - PubMed
    1. Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, et al. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial. Radiother Oncol. 2018;127:206–212. doi: 10.1016/j.radonc.2018.02.029. - DOI - PubMed
    1. Zelefsky MJ, Kollmeier M, McBride S, Varghese M, Mychalczak B, Gewanter R, et al. Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019;1(104):42e49. doi: 10.1016/j.ijrobp.2018.12.045. - DOI - PMC - PubMed

Substances